AXSM News and Press, Axsome Therapeutics Inc. From 02/22/23

Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical studies in Europe and MENA NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Axsome T...

Summary Teva filed an ANDA challenge against Auvelity four months after approval. The filing defines, for me, the hurdles generics will face in challenging Axsome's huge patent estate. Expect more filings in the next 12-18 months, but these are not major hurdles for Axsome. ...

Summary Anda's revenue generated $450 million for the company in the last three months of 2022, up $95 million from Q4 2022, driven by substantially increased demand for the company's services. Teva's European segment profit was $1,496 million in 2022, slightly up year-over-year, even t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Blue Planet Studio / Shutterstock.com Meta Platforms (NASDAQ: META ) layoffs are a hot topic among traders Monday as the Facebook parent company reportedly considering more job cuts . According to these r...

Axsome Therapeutics ( NASDAQ: AXSM ) traded lower in the morning hours Monday after announcing that Teva Pharmaceuticals ( NYSE: TEVA ) has filed for a generic version of its newly FDA-approved depression therapy Auvelity in the U.S. In a regulatory filing, Axsome ( AXSM )...

The biotech industry is home to many large and prominent corporations, but there are also smaller and lesser-known drugmakers that are worth investors' consideration. Take Axsome Therapeutics (NASDAQ: AXSM) and Exelixis (NASDAQ: EXEL) , two mid-cap biotechs with plenty to look for...

A last-minute three-pointer at the buzzer that you have no doubt will go in the basket. A job interview where you were at the top of your game. A stock with tremendous growth prospects. Some things you just know will be successful. With this in mind, we asked three Motley Fool contributors to...

We're getting ever so close to a new bull market. Another few days of gains for the S&P 500 could officially put the major index back in bull territory. But as the old saying goes, "Close only counts in horseshoes and hand grenades." There's no guarantee that the S&P will move th...

Summary Major Depressive Disorder (MDD) affects millions of people globally, with many still experiencing persistent symptoms despite current treatments. Auvelity, a combination of dextromethorphan and bupropion developed by Axsome Therapeutics, is attracting attention as an alternative...

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Offi...